Institution Directory

Clinical trials at Columbia University Irving Medical Center

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 12:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1202

Shown on this page

Current sort

Live official records

Conditions: Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors, HER2-positive Metastatic Breast Cancer, KRAS Mutant Metastatic Colorectal Cancer, Metastatic Lung Cancer, Metastatic Colorectal Cancer, Advanced Lung Cancer, HR-positive, HER2-negative Advanced Breast Cancer, HER2-positive Advanced Breast Cancer
Interventions: BBO-10203, Trastuzumab, Fulvestrant, Ribociclib, FOLFOX, Bevacizumab; Drug
Lead sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics); Industry
Eligibility: 18 Years and older
Enrollment: 392 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 19
States / cities: Duarte, California • Los Angeles, California • San Diego, California + 13 more

Conditions: Acanthamoeba Keratitis
Interventions: Polyhexamethylene biguanide (PHMB), Topical corticosteroid, Topical placebo; Drug · Other
Lead sponsor: Jeremy Keenan, MD, MPH; Other
Eligibility: 8 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 18
States / cities: Irvine, California • Los Angeles, California • San Francisco, California + 13 more

Conditions: Desmoid Fibromatosis, Recurrent Desmoid Fibromatosis, Unresectable Desmoid Fibromatosis
Interventions: Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Nirogacestat Hydrobromide, Quality-of-Life Assessment, Questionnaire Administration, X-Ray Imaging; Procedure · Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 12 Months to 18 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2032
U.S. locations: 89
States / cities: Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 73 more

Conditions: Parkinson Disease
Interventions: AAV2-GDNF gene therapy, control surgery; Drug · Procedure
Lead sponsor: AskBio Inc; Industry
Eligibility: 45 Years to 75 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 34
States / cities: Phoenix, Arizona • Irvine, California • Loma Linda, California + 26 more

Conditions: Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Grade 3b Follicular Lymphoma, HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Intravascular Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Nodular Lymphocyte Predominant B-Cell Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions: Biospecimen Collection, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Multigated Acquisition Scan, Oral Azacitidine, Positron Emission Tomography, Prednisone, Questionnaire Administration, Rituximab, Rituximab and Hyaluronidase Human, Vincristine Sulfate; Procedure · Drug · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 75 Years and older
Enrollment: 422 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 176
States / cities: Tucson, Arizona • Little Rock, Arkansas • Anaheim, California + 136 more

Conditions: Alagille Syndrome
Interventions: Not listed
Lead sponsor: Ipsen; Industry
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 10
States / cities: Los Angeles, California • San Francisco, California • Kansas City, Missouri + 6 more

Conditions: Primary Membranous Nephropathy
Interventions: Obinutuzumab, Tacrolimus, Methylprednisolone, Acetaminophen, Diphenhydramine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 8
States / cities: San Francisco, California • Aurora, Colorado • Altamonte Springs, Florida + 5 more

Conditions: Glioblastoma
Interventions: Photon Beam Radiation Therapy, Proton Beam Radiation Therapy, Temozolomide; Radiation · Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 624 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2030
U.S. locations: 230
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 179 more

Conditions: Glioblastoma
Interventions: Temozolomide, Lomustine, Regorafenib, Radiation, Paxalisib, VAL-083, VT1021, Troriluzole, ADI-PEG 20, AZD1390, Tinostamustine; Drug · Radiation · Biological
Lead sponsor: Global Coalition for Adaptive Research; Other
Eligibility: 18 Years and older
Enrollment: 2,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 42
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 31 more

Conditions: Extensive Stage-small Cell Lung Cancer
Interventions: Ifinatamab deruxtecan, Atezolizumab, Carboplatin; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 26
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more

Conditions: Breast Adenocarcinoma
Interventions: Bevacizumab, Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Placebo Administration, Quality-of-Life Assessment; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 4,994 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2027
U.S. locations: 840
States / cities: Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 548 more

Conditions: Mitral Valve Regurgitation
Interventions: Mitral valve repair, Transcatheter edge-to-edge repair; Procedure · Device
Lead sponsor: Annetine Gelijns; Other
Eligibility: 60 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2034
U.S. locations: 29
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 19 more

About this Columbia University Irving Medical Center institution page

What this page lists: ClinicalTrials.gov records that list Columbia University Irving Medical Center in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Columbia University Irving Medical Center

Filter and sort this campus

Live official records

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Parasitic Ulcer Treatment Trial

A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery

A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment

A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy

Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

Percutaneous or Surgical Repair In Mitral Prolapse And Regurgitation for ≥60 Year-olds (PRIMARY)

About this Columbia University Irving Medical Center institution page